Item No: 800000401
Product Name: Scyfix 700
Product Type: Treatment for Retinitis Pigmentosa and Dry Age-Related Macular Degeneration (“ARMD”)
ScyFIX micro-current neuromodulation (MCN) has been successful in treating other degenerative eye diseases like Macular Degeneration (ARMD), and is expected to become the standard of care for these blindness-causing diseases. ARMD is a major cause for the deterioration of eyesight in older age groups, affecting an estimated 50+ million people world-wide. It is estimated that 5% of the entire world population will develop a form of ARMD.
The ScyFIX 700 MCN device is approved for use in Europe (CE MARK). The ScyFIX MCN solution is expected to become the therapy of choice for other low-vision blindness causing diseases like Diabetic Retinopathy, Stargardt’s, Open Angle Glaucoma, CMV-Retinitis, as well as Presbyopia. More than 2000 people have been successfully treated with MCN Therapy. ScyFIX intends to become the world leader in the distribution of effective, non-invasive therapies for the treatment of chronic eye disorders.
Compelling Clinical Results: Retinitis Pigmentosa (RP) is a degenerative disease, and improvement in visual fields, visual acuity, or contrast sensitivity is not expected. In the RP trial, best corrected visual acuity either improved or remained stable in 94% of patients and improved in 22% of the population. Visual field improved in 63% of the patients. Patients are now using mobile phones, reading newspapers, seeing faces of family members and threading needles, none of these day to day activities were possible for these patients before using the ScyFIX MCN device. Similar compelling results have been achieved in our Dry Age-Related Macular Degeneration (“ARMD”) trial as well.
The ScyFIX 700 Therapy Kit includes a ScyFIX 700 micro current neuromodulator, wires, 24 sets of pads with electrodes (approx. 6 months), AC/DC adapters for EU, UK and North American standards, and an instruction manual in English.